Insider · CIK 0001836067
Jonathan Rubin
Files at SUPN (SUPERNUS PHARMACEUTICALS, INC.). First filing -, latest -.
In brief
Jonathan Rubin files SEC Form 4 as officer at SUPN (SUPERNUS PHARMACEUTICALS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jonathan Rubin has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 42 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +750 | $0.00 | $0 | 14,342 | Aug 14, 2026 |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -363 | $46.57 | $17k | 13,979 | Aug 14, 2026 |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -750 | $0.00 | $0 | 0 | Aug 14, 2026 |
| Jul 29, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +750 | $0.00 | $0 | 750 | Jul 31, 2026 |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +1,250 | $0.00 | $0 | 14,016 | Feb 26, 2026 |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -675 | $50.69 | $34k | 13,341 | Feb 26, 2026 |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -1,250 | $0.00 | $0 | 1,250 | Feb 26, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +1,125 | $0.00 | $0 | 12,409 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -603 | $51.35 | $31k | 11,806 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +750 | $0.00 | $0 | 12,556 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -369 | $50.86 | $19k | 12,187 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +1,250 | $0.00 | $0 | 13,437 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -671 | $0.00 | $0 | 12,766 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -1,125 | $0.00 | $0 | 3,375 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -750 | $0.00 | $0 | 0 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -1,250 | $0.00 | $0 | 2,500 | Feb 25, 2026 |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Employee Stock Option (Right to Buy)derivative | +13,500 | $0.00 | $0 | 13,500 | Feb 20, 2026 |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitderivative | +3,000 | $0.00 | $0 | 3,000 | Feb 20, 2026 |
| Sep 25, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +1,875 | $0.00 | $0 | 11,855 | Sep 26, 2025 |
| Sep 25, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -840 | $46.21 | $39k | 11,015 | Sep 26, 2025 |
| Sep 25, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -1,875 | $0.00 | $0 | 0 | Sep 26, 2025 |
| Sep 10, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +1,875 | $0.00 | $0 | 1,875 | Sep 12, 2025 |
| Dec 27, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +750 | $0.00 | $0 | 5,822 | Dec 30, 2024 |
| Dec 27, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -281 | $35.59 | $10k | 5,541 | Dec 30, 2024 |
| Dec 27, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +1,875 | $0.00 | $0 | 7,416 | Dec 30, 2024 |
| Dec 27, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -821 | $35.59 | $29k | 6,595 | Dec 30, 2024 |
| Dec 27, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -750 | $0.00 | $0 | 0 | Dec 30, 2024 |
| Dec 27, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -1,875 | $0.00 | $0 | 0 | Dec 30, 2024 |
| Dec 23, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +750 | $0.00 | $0 | 750 | Dec 26, 2024 |
| Dec 23, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +1,875 | $0.00 | $0 | 1,875 | Dec 26, 2024 |
| Feb 23, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +1,250 | $0.00 | $0 | 5,208 | Feb 27, 2024 |
| Feb 23, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -567 | $29.06 | $16k | 4,641 | Feb 27, 2024 |
| Feb 23, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -1,250 | $0.00 | $0 | 3,750 | Feb 27, 2024 |
| Feb 22, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +750 | $0.00 | $0 | 4,261 | Feb 26, 2024 |
| Feb 22, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -303 | $27.94 | $8,466 | 3,958 | Feb 26, 2024 |
| Feb 22, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -750 | $0.00 | $0 | 1,500 | Feb 26, 2024 |
| Feb 22, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitderivative | +5,000 | $0.00 | $0 | 5,000 | Feb 26, 2024 |
| Feb 22, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Employee Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Feb 26, 2024 |
| Dec 22, 2023 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +600 | $0.00 | $0 | 3,447 | Dec 26, 2023 |
| Dec 22, 2023 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -204 | $27.66 | $5,643 | 3,243 | Dec 26, 2023 |
| Dec 22, 2023 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -600 | $0.00 | $0 | 0 | Dec 26, 2023 |
| Dec 14, 2023 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +600 | $0.00 | $0 | 600 | Dec 18, 2023 |
Questions about Jonathan Rubin
Answered from the filings on this page, as of the latest one.
Is Jonathan Rubin buying or selling?
Jonathan Rubin has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jonathan Rubin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jonathan Rubin has 0.
Where does Jonathan Rubin file Form 4?
Jonathan Rubin has filed Form 4 at SUPN (SUPERNUS PHARMACEUTICALS, INC.) as SVP, Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.